5441722026-07-012026-09-305441722026-09-305441722026-03-315441722026-04-012026-09-305441722026-07-012026-09-30in-capmkt:OtherExpenses1Member5441722026-04-012026-09-30in-capmkt:OtherExpenses1Member5441722026-09-30OtherNoncurrentFinancialAssetsDomain15441722026-09-30OtherNoncurrentAssetsDomain15441722026-09-30OtherNoncurrentAssetsDomain25441722026-09-30OtherCurrentFinancialAssetsDomain15441722026-09-30OtherCurrentAssetsDomain15441722026-09-30OtherNoncurrentFinancialLiabilitiesDomain15441722026-09-30OtherNoncurrentFinancialLiabilitiesDomain25441722026-09-30OtherCurrentFinancialLiabilitiesDomain15441722026-09-30OtherCurrentFinancialLiabilitiesDomain25441722026-09-30OtherCurrentLiabilitiesDomain15441722026-07-012026-09-30in-capmkt:ReportableSegments1Member5441722026-07-012026-09-30in-capmkt:ReportableSegments2Member5441722026-07-012026-09-30in-capmkt:ReportableSegments3Member5441722026-04-012026-09-30in-capmkt:ReportableSegments1Member5441722026-04-012026-09-30in-capmkt:ReportableSegments2Member5441722026-04-012026-09-30in-capmkt:ReportableSegments3Member5441722026-07-012026-09-30in-capmkt:ReportableSegments1Member5441722026-07-012026-09-30in-capmkt:ReportableSegments2Member5441722026-07-012026-09-30in-capmkt:ReportableSegments3Member5441722026-04-012026-09-30in-capmkt:ReportableSegments1Member5441722026-04-012026-09-30in-capmkt:ReportableSegments2Member5441722026-04-012026-09-30in-capmkt:ReportableSegments3Member5441722026-07-012026-09-30in-capmkt:ReportableSegments1Member5441722026-09-30in-capmkt:ReportableSegments1Member5441722026-07-012026-09-30in-capmkt:ReportableSegments2Member5441722026-09-30in-capmkt:ReportableSegments2Member5441722026-07-012026-09-30in-capmkt:ReportableSegments3Member5441722026-09-30in-capmkt:ReportableSegments3Member5441722026-07-012026-09-30in-capmkt:ReportableSegments1Member5441722026-09-30in-capmkt:ReportableSegments1Member5441722026-07-012026-09-30in-capmkt:ReportableSegments2Member5441722026-09-30in-capmkt:ReportableSegments2Member5441722026-07-012026-09-30in-capmkt:ReportableSegments3Member5441722026-09-30in-capmkt:ReportableSegments3Member5441722026-07-012026-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15441722026-04-012026-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15441722026-07-012026-09-30ItemsThatWillBeReclassifiedToProfitAndLoss15441722026-07-012026-09-30ItemsThatWillBeReclassifiedToProfitAndLoss25441722026-04-012026-09-30ItemsThatWillBeReclassifiedToProfitAndLoss15441722026-04-012026-09-30ItemsThatWillBeReclassifiedToProfitAndLoss25441722026-07-012026-09-30AuditorDomain1iso4217:INRiso4217:INRxbrli:shares544172INDGNNOTLISTEDINE065X01017Indegene LimitedMain BoardEquity2026-04-012027-03-312026-10-292026-09-30INRMillionsQuarterlySecond quarterMulti segment2026-10-2918:30:002026-10-2919:16:00trueCash Flow IndirectDeclaration of unmodified opinion2026-07-012026-09-30UnauditedConsolidated112230000001500000001137300000000068170000006900000046400000025490000009899000000147400000001474000000411000000-6000000035100000001123000000000011230000002100000001333000000112300000021000000048100000024.674.64004.674.64Notes to the Statement of Consolidated Financial Results for the quarter and six months ended 30 September 2026 <br /> All amounts in INR millions except share data and where otherwise stated <br /> <br /> 1 The above Consolidated Financial Results of Indegene Limited the Company or the Parent or the Holding Company together with its affiliates collectively the Group have been prepared in accordance with Indian Accounting Standards Ind AS 34 Interim Financial Reporting recognition and measurement principles of Indian Accounting Standards Ind AS prescribed under Section 133 of the Companies Act 2013 as amended read with the relevant rules issued thereunder and in terms of Regulation 33 of the SEBI Listing Obligations and Disclosure Requirements Regulations 2015 the Regulations Due to rounding off the numbers presented throughout may not add up precisely to the totals in the financial information Caret symbol denote amounts less than INR 5 lakhs <br /> <br /> 2 The above Consolidated Financial Results have been reviewed by the Audit Committee in the meeting held on 28 October 2026 and approved by the Board of Directors at its meeting held on 29 October 2026 The statutory auditors have performed a limited review of the Consolidated Financial Results for the quarter and six months ended 30 September 2026 and have issued an unmodified review report on the same <br /> <br /> 3 The Consolidated Financial Results for the quarter and six months ended 30 September 2026 are available on the National Stock Exchange of India Limited URL www nseindia com the BSE Limited website URL www bseindia com and on the Companys website URL www indegene com investorrelations <br /> <br /> 7 Exception Item Litigation Expenses <br /> During the financial year 2020 and 2021 Indegene Inc a subsidiary of the Company was named in a class action lawsuit filed in the U S District Court of New Jersey alleging non compliance with the Telephone Consumer Protection Act of 1991 TCPA by sending unsolicited fax advertisements without the recipients prior express invitation or permission <br /> <br /> Plaintiff initiated this matter through the filing of its Class Action Complaint against Indegene Inc Indegene Encima Inc Indegene Wincere Inc and Indegene Healthcare LLC collectively Indegene or Defendants seeking the Court to award actual monetary loss from the alleged TCPA violations in an amount to be proven in Court or the sum of USD 500 for each violation whichever is greater and that the Court award treble damages of USD 1500 if the violations are deemed wilful or knowing Additionally the Plaintiff seeks the Court award prejudgment interest and costs to be determined upon presentation of suitable evidentiary support <br /> <br /> During the year ended 31 March 2026 the matter progressed to mediation and the Group agreed in principle to a mediator proposed settlement framework under which the Defendants would make available a maximum settlement fund of approximately INR417 or USD 4 millions and 720 thousands calculated at USD 250 per eligible claim The settlement is structured as a claims made arrangement whereby the actual outflow is contingent upon valid claims submitted by eligible class members and unclaimed amounts if any revert to the Group in accordance with the settlement terms Accordingly the maximum settlement fund does not represent the expected cash outflow <br /> <br /> Based on the status of the proceedings and the Groups assessment supported by external legal advice the Group concluded that a present obligation existed and that an outflow of economic resources was probable and can be reliably estimated Accordingly the Group recognised a provision of INR203 or USD 2 millions and 300 thousands including estimated legal costs representing its best estimate of the expenditure required to settle the obligation which has been disclosed as exceptional item in the results for the year ended 31 March 2026 During the period ended 30 September 2026 pursuant to the courts orders the class administrator has issued notices to class members on 10 September 2026 requesting to submit claim forms or opt out of the settlement wherein the Class members have until 09 December 2026 to submit the claims or opt out The Settlement payments are expected to become payable following the final fairness hearing and Court approval in accordance with the settlement terms The amount payable will depend on valid claims submitted and attorneys fees awarded by the Court to the Plaintiffs counsel The ultimate outflow will be subject to the claims process and final Court approval Accordingly the Group does not estimate any change in amount of provision as at 30 September 2026 <br /> <br /> 8 The shareholders approved a final dividend of INR 2 and 25 paise per equity share for the financial year ended 31 March 2026 at the 28th Annual General Meeting held on 13 August 2026 The dividend was paid on 21 August 2026 resulting in a cash outflow of INR 5422026-04-012026-09-30UnauditedConsolidated2185400000044000000022294000000000134080000001330000009050000004847000000192930000003001000000030010000007040000001200000071600000002285000000000022850000003280000002613000000228500000032800000048100000029.59.44009.59.44Other Expenses2549000000Other Expenses48470000002285000000001160900000044040000000000002270000002270000007630000007100000019359000000010191000000114500000001414000000955000000014830000002549300000070900000013720000002757400000046933000000481000000331030000003358400000003358400000000001258000000125800000091300000000217100000005400000019470000002001000000467000000066710000003413000000903000000191000000011178000000001334900000046933000000Notes to the Statement of Consolidated Financial Results for the quarter and six months ended 30 September 2026 <br /> All amounts in INR millions except share data and where otherwise stated <br /> <br /> 4 Acquisition of Cake Kommunikations <br /> On 10 November 2025 the Group had entered into a stock purchase agreement to acquire Cake Kommunikations Holdings GmbH an SPV created to hold 70 percent in Cake Kommunikations GmbH AT 100 percent in CAKE Kommunikations GmbH DE and 100 percent in CAKE Kommunikations AG Switzerland and 30 percent in Cake Kommunikations GmbH AT from Werner Hinterberger Collectively Cake Group for an aggregate purchase consideration of INR 873 or EUR 8 millions 90 thousand including deferred and contingent consideration <br /> <br /> Further on 30 January 2026 the Group had obtained control of Cake Group The Cake Group is an advertising agency specialized in healthcare and pharmaceutical communication The acquisition was consummated at a consideration of INR 873 which includes earnout component of INR 383 or EUR 3 millions and 550 thousands and an unconditional management incentive of INR 15 or EUR 140 thousand The earnout component is based on the performance of Cake during the period commencing on 1 April 2025 till 31 March 2028 with the range of earnout from Nil to INR 470 or EUR 4 millions and 350 thousands while the unconditional management incentive of INR 15 or EUR 140 thousand falls due on 1 June 2028 <br /> <br /> The Group believes that the acquisition will enable the Group to expand its healthcare marketing and communication capabilities in Europe specifically targeting the DACH region Germany Austria and Switzerland thereby strengthening the Groups footprint by offering specialized hightouch marketing services The Group concluded that the acquired set was a business and did the provisional PPA during the year ended 31 March 2026 The same has been finalised during the period ended 30 September 2026 <br /> <br /> The following table presents the allocation of purchase price based on final PPA <br /> Net assets taken over Acquiree s carrying amount is INR 125 <br /> Identifiable intangibles assets Customer relationship Fair value adjustment is INR 283 <br /> Total identifiable intangible assets acquired is INR 283 <br /> Total is INR 408 <br /> Goodwill is INR 465 <br /> Total Purchase consideration is INR 873 <br /> <br /> The fair value of net assets acquired including the identified intangibles as on the acquisition date as a part of the transaction amounted to INR 408 The excess of purchase consideration over the fair value of net assets acquired has been attributed towards goodwill The goodwill of INR 465 comprises value of acquired workforce and expected synergies arising from the acquisition Net assets acquired included INR 4 INR 107 INR 111 INR 24 INR 8 INR 7 INR 71 and INR 51 of Fixed Assets Cash and cash equivalents trade receivable unbilled revenue other assets accounts payable other liabilities and borrowings respectively None of the trade receivables have been impaired and it is expected that its full contractual amount can be collected Goodwill is allocated to Enterprise Commercial Solutions segment and is not deductible for income tax purposes of respective country tax laws The aggregate cost incurred for the acquisition is INR 53 <br /> <br /> 5 During the period ended 30 September 2026 Indegene Healthcare Germany GmbH and Trilogy Writing and Consulting GmbH wholly owned subsidiaries of Indegene Ireland Limited and the stepdown subsidiaries of the Company entered into a merger agreement dated 22 July 2026 pursuant to which Indegene Healthcare Germany GmbH was merged into Trilogy Writing and Consulting GmbH effective 01 April 2026 The merger was done by way of a statutory merger by absorption under German laws under which all assets liabilities rights and obligations of Indegene Healthcare Germany GmbH were transferred to Trilogy Writing and Consulting GmbH and the transferor entity ceased to exist upon completion of the merger Following the merger Trilogy Writing and Consulting GmbH was renamed as Indegene Healthcare Germany GmbHOther financial assets227000000Non-current tax assets (net)37000000Other non-current assets34000000Other financial assets1483000000Other current assets1372000000Lease liabilities1156000000Other financials liabilities102000000Other financial liabilities4253000000Lease liabilities417000000Other current liabilities3413000000Enterprise Medical Solutions2753000000Enterprise Commercial Solutions8002000000Others468000000Enterprise Medical Solutions5489000000Enterprise Commercial Solutions15504000000Others8610000001122300000021854000000001122300000021854000000Enterprise Medical Solutions626000000Enterprise Commercial Solutions1302000000Others3000000Enterprise Medical Solutions1342000000Enterprise Commercial Solutions2499000000Others-112000000193100000037290000006900000013300000038800000059500000014740000003001000000Enterprise Medical Solutions0Enterprise Commercial Solutions0Others0000Enterprise Medical Solutions0Enterprise Commercial Solutions0Others0000Notes to the Statement of Consolidated Financial Results for the quarter and six months ended 30 September 2026 <br /> All amounts in INR millions except share data and where otherwise stated <br /> <br /> 6 Segment information <br /> During the year ended 31 March 2026 the Group effective 01 October 2025 has reorganised its segments by merging Brand Activation Segment as part of Enterprise Commercial Solutions in line with the manner in which the chief operating decision maker reviews and evaluates performance of the business of the Group Pursuant to the above in accordance with the requirement specified in Ind AS 108 the comparative period information has been recasted to give the effect of this change <br /> As a consequence the Group currently has 2 reportable segment i e Enterprise Commercial Solutions and Enterprise Medical Solutions <br /> <br /> Operating segments are identified as components of an enterprise for which discrete financials information is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and assessing performance The Groups chief operating decision maker is the Chief Executive Officer and Executive Director <br /> <br /> Assets and liabilities used in the Groups business are not identified to any of the operating segments as these are used interchangeably between segments Management believes that it is currently not practicable to provide segment disclosures relating to total assets and liabilities since a meaningful segregation of the available data is onerous <br /> <br /> Others mainly comprises of consultancy and clinical business1180000000-1625000000048000000000000-73300000009050000000145000000000-24400000067000000680000001290000000000-2380000000-1630000000137100000000015040000000-133000000000000000251000000000000000000000000210000000-390000000-6200000000090000000000000260000000542000000000-793000000-1546000000-48000000-159400000030080000001414000000Remeasurement of defined benefit obligation5200000052000000Remeasurement of defined benefit obligation2300000023000000130000006000000Exchange differences on translating the financial statements of foreign operations218000000Net change in fair value of forward contracts designated as cash flow hedges-63000000155000000Exchange differences on translating the financial statements of foreign operations315000000Net change in fair value of forward contracts designated as cash flow hedges-5000000310000000-16000000-1000000210000000328000000UnauditedtrueDeloitte Haskins & Sellstrue2028-04-30